Kronos Bio, Inc.
KRON evidence brief
What we can confirm
- BioSniper Score:
- 6.0 / 10
- Lead Asset:
- kb-0742 (Phase 2)
What it means
What to watch
Prepared research question
What matters most for KRON—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Market Cap
—
Cash Runway
—
Lead Asset
kb-0742 (Phase 2)
Next Catalyst
—
Tracking 3 pipeline candidates for Kronos Bio, Inc..
Run Kronos Bio, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Kronos Bio, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Score breakdownBased on 2 of 6 signals · derived from public data
Cash runway data unavailable
Financial health data unavailable
Lead: Phase 2
3 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Frequently asked questions
What is Kronos Bio, Inc.'s lead drug candidate?
Kronos Bio, Inc.'s most advanced tracked candidate is kb-0742 (Phase 2) for MYC-amplified and other transcriptionally addicted solid tumors.
Who is the CEO of Kronos Bio, Inc.?
Norbert Bischofberger, Ph.D. is the chief executive officer of Kronos Bio, Inc. (KRON).
What therapeutic areas does Kronos Bio, Inc. focus on?
Kronos Bio, Inc. develops therapies across Oncology, Immunology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.